Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies (Q34560528)

3 August 2017

1 reference

title

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies (English)

1 reference

3 August 2017

0 references

Marinos C Dalakas

1

1 reference

3 August 2017

publication date

1 August 2006

1 reference

Nature Clinical Practice Neurology

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

437-447

1 reference

Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Differential expression of chemokines in inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

DNA microarray gene expression analysis technology and its application to neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis: new concepts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis and myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-β, misfolded proteins, predisposing genes, and aging

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Prevalence of sporadic inclusion body myositis in Western Australia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis: no evidence for a neurogenic component

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Disease progression in sporadic inclusion body myositis: observations in 78 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis: clinical and pathological boundaries

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Apolipoprotein E epsilon 4 in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis and paraproteinemia: Incidence and immunopathologic correlations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inflammatory, immune, and viral aspects of inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Immunobiology of muscle: advances in understanding an immunological microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Molecular immunology and genetics of inflammatory muscle diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

T-cell heterogeneity in muscle lesions of inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Expression of IFN-gamma-inducible chemokines in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Inclusion body myositis in HIV-1 and HTLV-1 infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Tapasin: an ER chaperone that controls MHC class I assembly with peptide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Recent developments in MHC-class-I-mediated antigen presentation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Aggresomes and autophagy generate sites for virus replication

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Therapeutic approaches in patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0261

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0261

1 reference

3 August 2017

1 reference